Herpes Zoster (Shingles) - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 68 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Herpes Zoster (Shingles) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Herpes Zoster (Shingles) - Pipeline Review, H1 2016', provides an overview of the Herpes Zoster (Shingles) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Herpes Zoster (Shingles), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles)
- The report reviews pipeline therapeutics for Herpes Zoster (Shingles) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Herpes Zoster (Shingles) therapeutics and enlists all their major and minor projects
- The report assesses Herpes Zoster (Shingles) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Herpes Zoster (Shingles)

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Herpes Zoster (Shingles)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Content
Table of Contents 2

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Herpes Zoster (Shingles) Overview 7
Therapeutics Development 8
Pipeline Products for Herpes Zoster (Shingles) - Overview 8
Herpes Zoster (Shingles) - Therapeutics under Development by Companies 9
Herpes Zoster (Shingles) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Herpes Zoster (Shingles) - Products under Development by Companies 14
Herpes Zoster (Shingles) - Companies Involved in Therapeutics Development 15
Astellas Pharma Inc. 15
Beijing Minhai Biotechnology Co., Ltd 16
ContraVir Pharmaceuticals, Inc. 17
Epiphany Biosciences, Inc. 18
Foamix Pharmaceuticals Ltd. 19
GeneOne Life Science, Inc. 20
GlaxoSmithKline Plc 21
Merck & Co., Inc. 22
NAL Pharmaceuticals Ltd. 23
ReceptoPharm, Inc. 24
TSRL, Inc. 25
Herpes Zoster (Shingles) - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
acyclovir - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
amenamevir - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
FV-100 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
GLS-5100 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
GSK-1437173A - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
herpes zoster vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
NAL-3221 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
NAL-3223 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
RPI-78M - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
TSR-087 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
V-212 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
valomaciclovir stearate - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Herpes Zoster (Shingles) - Recent Pipeline Updates 52
Herpes Zoster (Shingles) - Dormant Projects 58
Herpes Zoster (Shingles) - Discontinued Products 59
Herpes Zoster (Shingles) - Product Development Milestones 60
Featured News & Press Releases 60
Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study 60
Oct 27, 2015: GSK's candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over 60
Sep 08, 2015: Clinical trial for Cardiff's shingles treatment 61
Aug 03, 2015: ContraVir Pharmaceuticals Enrolls First Patient in Pivotal Phase 3 Study of FV-100 for Treatment of Shingles and Shingles-Associated Pain 62
Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial 62
Apr 28, 2015: GSK candidate vaccine for the prevention of shingles demonstrates overall efficacy of 97.2% which does not diminish in the age groups studied 63
Mar 09, 2015: ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN 64
Dec 18, 2014: Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint 64
Dec 18, 2014: Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant 65
Dec 09, 2014: ContraVir Pharmaceuticals Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles 66
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 67
Disclaimer 68

List of Tables

Number of Products under Development for Herpes Zoster (Shingles), H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Comparative Analysis by Unknown Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Herpes Zoster (Shingles) - Pipeline by Astellas Pharma Inc., H1 2016 15
Herpes Zoster (Shingles) - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016 16
Herpes Zoster (Shingles) - Pipeline by ContraVir Pharmaceuticals, Inc., H1 2016 17
Herpes Zoster (Shingles) - Pipeline by Epiphany Biosciences, Inc., H1 2016 18
Herpes Zoster (Shingles) - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016 19
Herpes Zoster (Shingles) - Pipeline by GeneOne Life Science, Inc., H1 2016 20
Herpes Zoster (Shingles) - Pipeline by GlaxoSmithKline Plc, H1 2016 21
Herpes Zoster (Shingles) - Pipeline by Merck & Co., Inc., H1 2016 22
Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd., H1 2016 23
Herpes Zoster (Shingles) - Pipeline by ReceptoPharm, Inc., H1 2016 24
Herpes Zoster (Shingles) - Pipeline by TSRL, Inc., H1 2016 25
Assessment by Monotherapy Products, H1 2016 26
Number of Products by Stage and Target, H1 2016 28
Number of Products by Stage and Mechanism of Action, H1 2016 30
Number of Products by Stage and Route of Administration, H1 2016 32
Number of Products by Stage and Molecule Type, H1 2016 34
Herpes Zoster (Shingles) Therapeutics - Recent Pipeline Updates, H1 2016 52
Herpes Zoster (Shingles) - Dormant Projects, H1 2016 58
Herpes Zoster (Shingles) - Discontinued Products, H1 2016 59